Skin Cancer

P4, N=40, Not yet recruiting, The University of Sydney

Agreed positions included caution with JAK inhibitors (JAKi) in older patients and in those with CV/VTE risk; preference for IL-6 receptor inhibitors or JAKi for monotherapy or prominent systemic inflammation; in RA-ILD, use a b/tsDMARD with a non-TNFi mechanism; rituximab as first choice in rheumatoid vasculitis; abatacept in infection-prone patients; discouraging JAKi in prior malignancy; and TNFi as acceptable during pregnancy. Two statements did not reach consensus: preferential use of non-TNFi in obesity and heightened caution with tofacitinib in osteoporosis or fracture risk. This Delphi-validated, profile-based framework provides a practical tool to support evidence-informed clinical decision-making.

Postoperative adjuvant therapy included systemic chemotherapy and targeted therapy. No recurrence was observed during the 2-year follow-up period.

P2, N=49, Active, not recruiting, Universitair Ziekenhuis Brussel

Nivolumab showed durable antitumour activity with manageable toxicity in Japanese patients with advanced NMSCs, including rare non-cSCC. The lower ORR compared with Western trials may reflect intrinsic biological differences and support biomarker-driven, region-specific immunotherapy.

RRM2 and PRPS1 are pivotal purine metabolism-related genes affecting KD pathogenesis, providing insights for KD diagnosis and therapeutic targets.

In vitro, B cells engineered to be specific for viral oncoproteins increased the sensitivity of oncoprotein-specific CD4+ T cells by over 50-fold. Together, our findings suggest that cancer-specific B cells promote antitumor immunity via increased responses by T cells and that cancer-specific augmentation of B cells could be therapeutically relevant.

A novel, highly selective, IKKα inhibitor (SU1644) used in patient derived CCS tumour spheroid cultures demonstrated that IKKα inhibition reduced tumour spheroid viability. These data provide the pre-clinical rationale for the assessment of topical IKKα inhibitors as a novel preventative treatment for CCS.

In conclusion, this work validates specific isoxazole derivatives as highly promising candidates for development: MO3 for resistant bacterial infections, MO7 for otherwise untreatable adenovirus infections, and MO10 as a dual-action agent against HSV-1 and an adjunct to melanoma chemotherapy.

Common events such as rash and dermatitis acneiform, as well as several less frequently described reactions, warrant heightened clinical vigilance, especially in older and male patients. Prospective and mechanistic studies are needed to confirm these associations and to refine strategies for preventing and managing cetuximab-induced skin toxicity.

P2, N=87, Recruiting, Psyence Australia Pty Ltd | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: May 2026 --> Dec 2026

P2/3, N=140, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026